If you are considering GLP-1 treatment for weight loss, waiting for a patch that may be years away from approval means delaying the benefits of treatment that is available now
This comes at a critical time: The GLP-1 injectable segment in India has exploded sales up ~177% YoY to 1,446 crore (MAT Feb 2026) driven by global blockbusters and rising obesity/diabetes burden (101M+ with diabetes, 136M+ pre-diabetes, hundreds of millions with obesity per WHO estimates)
The glucose-dependent nature of insulin secretion with GLP-1 therapy represents a significant safety advantage
$40.00 13 in stock 13 in stock This product is intended for laboratory research use only
JAMA Health Forum 2(12):e214182 Carney G, Kim JD, OSullivan C, Thompson W, Bassett K, Levin J et al (2022) Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada